Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

FRILLY: A Retrospective Single-centre Study on Fractionated Rituximab to Avoid Lysis Syndrome in Aggressive B-Lymphoma

NCT05840289 is registered in ClinicalTrials.gov with University Hospital, Geneva as lead sponsor.

NCT NCT05840289
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05840289 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
FRILLY: A Retrospective Single-centre Study on Fractionated Rituximab to Avoid Lysis Syndrome in Aggressive B-Lymphoma
Lead sponsor
University Hospital, Geneva
Phase
Observational
Overall status
Unknown status
Start date
August 24, 2020
Completion date
May 1, 2023
Enrollment
94 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

aggressive b-cell non-hodgkin lymphoma